<DOC>
	<DOCNO>NCT00002798</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness different chemotherapy regimen without bone marrow transplantation treat child acute myelogenous leukemia myelodysplastic syndrome . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . It yet know treatment regimen effective acute myelogenous leukemia myelodysplastic syndrome</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bone Marrow Transplantation Treating Children With Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : Increase remission induction rate great 85 % child untreated acute myelogenous leukemia ( AML ) myelodysplastic syndrome ( MDS ) replace daunorubicin ( DNR ) idarubicin ( IDA ) intensively time DCTER chemotherapy ( dexamethasone , cytarabine ( ARA-C ) , thioguanine , etoposide , daunorubicin ) first 4 day course . Increase remission rate compare efficacy consolidation chemotherapy intensively time IDA DCTER/DCTER v fludarabine ( FAMP ) , ARA-C , IDA maintain remission achieve remission patient M2 disease ( 5 % -29 % blast marrow ) end induction chemotherapy . Compare overall survival , event-free survival , disease-free survival patient receive consolidation IDA DCTER/DCTER v FAMP , ARA-C , IDA . Compare overall survival , event-free survival , disease-free survival patient receive intensification Capizzi II regimen ( high-dose ARA-C asparaginase ) v receive matched-related allogeneic bone marrow transplantation . Compare overall survival , event-free survival , disease-free survival patient treat interleukin-2 ( IL-2 ) v standard follow care Capizzi II intensification . Determine whether multichannel flow cytometry detection residual AML companion biologic study protocol CCG-B942 predicts outcome , determine whether treatment regimen eliminate minimal residual disease effectively another . Register patient MDS treat follow CCG institution capture biologic , historical outcome data . Determine , companion biologic study protocol CCG-B972 , whether level IL-2 soluble receptor ( sIL-2R ) absolute lymphocyte count ( ALC ) , , therapy correlate outcome . OUTLINE : This randomize , multicenter study . Patients stratify accord center , diagnosis ( acute myelogenous leukemia v ) , response induction ( partial v complete remission ) . After induction , patient M1/M2 marrow randomize arm I II . Patients complete remission consolidation HLA-identical 1-antigen mismatch sibling parent donor randomly assign allogeneic bone marrow transplantation ( AlBMT ) regimen ; others complete remission nonrandomly assign Capizzi II regimen , randomly assign arm III IV . Patients refractory anemia ( RA ) RA ring sideroblast indolent disease may register followed . Other patient myelodysplastic syndrome may receive 2961 chemotherapy go directly AlBMT . Patients chloromas ( granulocytic sarcoma ) receive optional radiotherapy arm V. Induction : Patients receive idarubicin IV 30 minute day 0-3 , cytarabine etoposide IV continuously day 0-3 , oral thioguanine twice day oral dexamethasone 3 time day day 0-3 . Patients begin course 2 , consist cytarabine , etoposide , thioguanine , dexamethasone day 10-13 , daunorubicin IV continuously day 10-13 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 16 continue blood count recover . Patients also receive CNS prophylaxis/therapy consist cytarabine intrathecally ( IT ) day 0 14 ( CNS disease entry ) day 0 , 5 , 7 ( CNS disease present entry ) . Disease reassess day 28-42 . Patients M1 M2 marrow proceed consolidation M3 marrow progressive disease go study . Consolidation : Arm I : Patients receive treatment induction therapy , plus G-CSF SC begin day 16 continue blood count recover . If CSF clear day 10 induction , patient receive cytarabine IT day 0 , 10 , 35 . If CSF clear , patient receive triple intrathecal therapy ( TIT ; cytarabine , hydrocortisone , methotrexate ) day 0 10 . Arm II : Patients receive fludarabine IV 24 hour day 0 1 , cytarabine IV 72 hour day 2-4 , idarubicin IV 15 minute day 0-2 . G-CSF begin day 6 continue blood count recover . Patients also receive TIT day -1 7 , CSF clear day 10 induction . Patients arm reassess day 35 . Those patient M1 marrow proceed intensification ; others remove study . Intensification : Capizzi II regimen : Course 1 : Patients receive cytarabine IV 3 hour every 12 hour day 0 , 1 , 7 , 8 asparaginase IM day 1 8 . Course 2 : Patients also receive cytarabine IT TIT day 0 , 7 , 14.AlBMT regimen : Therapy begin within 2-8 week hematologic recovery . Patients may receive interim therapy consist oral thioguanine 2 week . Patients receive oral busulfan every 6 hour day -9 -6 cyclophosphamide IV 1 hour day -5 -2 . AlBMT infuse 4 hour begin 36-48 hour last dose cyclophosphamide . Patients complete remission complete Capizzi II regimen proceed maintenance therapy arm III . Arm III : Patients receive interleukin-2 IV continuously day 1-4 9-18 . Arm IV : No treatment . Arm V : Patients undergo radiotherapy chloroma 5 day week 2 week . Patients follow monthly 18 month , every 3 month 1 year , every 6 month 5 year diagnosis . PROJECTED ACCRUAL : Approximately 880 patient de novo acute myelogenous leukemia accrue study within 4 year . It expect 178 patient per year randomly assign consolidation , 39 patient per year undergo allogeneic bone marrow transplantation 120 patient per year receive chemotherapy intensification , 102 patient per year randomly assign polychemotherapy immunomodulation . An additional 80 patient myelodysplastic syndrome accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Histologically confirm previously untreated acute myeloid leukemia ( AML ) patient 1 month 21 year age Infants 1 month progressive disease eligible Supportive care may give confirm leukemia regress prior entry No acute promyelocytic leukemia ( FAB M3 ) No acute undifferentiated leukemia ( FAB M0 ) Histochemical verification AML require follow stain : Wright Giemsa Peroxidase PAS Chloroacetate esterase Sudan black Nonspecific esterase ( NSE ) without fluoride ( NaF ) inhibition Combined NSE/NaF butyrate inhibition diagnosis megakaryoblasticleukemia ( FAB M7 ) support one following : CD41 reactivity Glycoprotein 1b reactivity Factor VIIIrelated antigen reactivity Platelet peroxidase electron microscopy The following also eligible : Myelodysplastic syndrome , include : Refractory anemia ( RA ) * RA ring sideroblast ( RARS ) * RA excess blast ( RAEB ) RAEB transformation ( RAEBt ) Chronic myelomonocytic leukemia ( CMML ) AML monosomy 7 Granulocytic sarcoma ( chloroma ) without marrow involvement Mixed lineage leukemia 2 morphologically defined population provide predominant population myeloid No Downs syndrome No juvenile chronic myelogenous leukemia No Fanconi 's anemia No secondary AML Performance status Not specify No prior anticancer chemotherapy Prior topical inhale steroid nonmalignant condition allow No prior anticancer radiotherapy No prior antileukemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>